Improved survival for Stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001

Background: The aim of this study was to evaluate the treatment of FIGO Stage IIIC patients who were primarily treated completely or partially at the Norwegian Radium Hospital (NRH) during a 15-year period in order to discover possibilities for improvement of prognosis of advanced ovarian cancer.

Materials and method: A retrospective study based on record information from all patients with epithelial ovarian cancer Stage IIIC treated at NRH from 1985-2000, in total 776 patients.

Results: We found age, amount of residual tumour after surgery for primary treatment and type of chemotherapy to be the most significant prognostic factors for overall survival. During the last 5-year period primary surgery was increasingly centralised, and surgery was improved with lymph node staging and use of paclitaxel. Survival was significantly better during the last 5-year period and after macroscopic radical surgery. Also progression-free survival was better with no macroscopic tumour remaining.

Interpretation: Improved survival during the last 5-year period is partly attributed to improved surgery and partly to the addition of paclitaxel. We believe that further centralisation of primary surgery for advanced ovarian cancer can contribute to a better prognosis.

Ovarian cancer; Survival

[1] Pecorelli S., Benedet J.L., Creasman W.T., Stephard J.H., Petterson F.: Annual report on the results of treatment in gynecological cancer. Vol 23, Oxford, UK, International Federation of Gynecology and Obstetrics, 2002.

[2] Cancer in Norway 2004. The Cancer Registry of Norway. Oslo, Norway.

[3] Bj0rge T., Engeland A., Sundf0r K., Trope C.: "Prognosis of 2800 patients with epithelial ovarian canser diagnosed during 1975-94 and treated at the Norwegian Radium Hospital". Acta Obstet. Gynecol. Scand., 1998, 77, 777.

[4] Aure J.C., Hoeg K., Kolstad P.: "Clinical and histologic studies of ovarian carsinoma. Long term follow-up of 990 cases". Obstet. Gynecol., 1971, 37, 1.

[5] Griffith C.T.: "Surgical resection of tumor bulk in the pnmary treatment of ovarian carsinoma". Natl Cancer Inst. Monogr., 1975, 42, 101.

[6] Lund B., Williamson P.: "Prognostic factors for overall survival in patients with advanced ovarian carsinoma". Ann. Oneal., 1991, 2, 281.

[7] Hoskins W.J.: "Primary surgical management of advanced epithelial ovarian cancer". In: Rubin S.C., Sutton G.P. (eds.). Ovarian cancer. New York, McGraw-Hill, 1993, 241.

[8] Makar A.P., Barkelandt M., Trope C.G., Kristensen G.B.: "The Prognostic Significance of Residual Disease, F IGO Substage, Tumour Histology, and Grade in Patients with FIGO Stage III Ovarian Cancer". Gynecol. Oneal., 1995, 56, 175.

[9] Eisenhauer E.A., Gore M., Neijt J.P.: "Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner?". Ann. Oncol., 1999 (suppl. 1), 9.

[10] Clark T.G., Stewart M.E., Altman D.G., Gabra H., Smyth J.F.: "A prognostic model of ovarian cancer". Br. J. Cancer, 2001, 85, 944.

[11] Bristow R.E. et al.: "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis". J. Clin. Oneal., 2002, 20, 1248.

[12] Eisenkop S.M., Spirtos N.M., F riedman R.L. et al.: "Relative influences of tumour volume before surgery and the cytoreductive outcome on survival of patients with advanced ovarian cancer: a prospective study". Gynecol. Oneal., 2003, 90, 390.

[13] Kaern J., Aghmesheh M., Nesland J.M., Danielsen H.E., Sandstad B., Friedlander M., Trope C.: "Prognostic factors in ovarian carcinoma Stage III patients. Can biomarkers improve the prediction of short- and long-term survivors')". Int. J. Gynecol. Cancer, 2005, 15, 1014.

[14] Kristensen G.B., Trope C.: "Epithelial ovarian carcinoma". Lancet, 1997, 349, 113.

[15] Aabo K., Adams M., Adnitt P. et al.: "Chemotherapy in advanced ovarian cancer: four systematic meta-analysis of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists'Group". Br. J. Cancer, 1998, 78, 1479.

[16] Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists'Group Br. Med. J., 1991, 12, 884.

[17] McGuire W.P., Hoskins W.J.. Brady M.F. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer". N. Engl. J. Med., 1996, 334.

[18] Piccart M.J., Bertelsen K., James K. et al.: "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results". J. Nat. Cancer Inst., 2000, 92, 699.

[19] Neijt J.P., Engholm S.A., Tuxen M.K. et al.: "Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer". J. Klin. Onkol., 2000, 18, 3084.

[20] Ozols R.F., Bundy B.N., Greer B.E. et al.: "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oneal., 2003, 21, 3194.

[21]du Bois A., Luck H.J., Meier W. et al.: "A randomized clinical trial of cisplatin/paclitaxel versus carbop!atin/paclitaxel as first line treatment of ovarian cancer". J. Natl. Cancer Inst., 2003, 95, 1320.

[22] 3''International ovarian cancer consensus of the GCIG. Ann. Oncol., 2005, 16 (suppl. 8), 36.

[23] Tingulstad S., Skjeldestad F.E., Hagen B.: "The effect of centralization of primary surgery on survival in ovarian cancer patients" Ohstet. Gynecol., 2003, 102, 499.

[24] Junor E.J., Hole D.J., McNulty L., Mason M., Young J.: "Spesialist gynecologists and survival outcome in ovarian cancer: a Scottish National Study of 1966 patients". Br. J. Ohstet. Gynecol., 1999, 106, 1130.

[25] Paulsen T., Kjærheim K., Kærn J., Tretli S., Trope C.: "Improved short-time survival for advanced ovarian, tubar and peritoneal cancer patients operated at teaching hospitals". Int. J. Gynecol Cancer, 2006, 16 (suppl. I), 11.

[26] Giede K.C., Kieser K., Dodge J., Rosen B.: "Who should operate on patients with ovarian cancer'J An evidence-based review". Gynecol. Oneal., 2005, 99, 447.

[27] Oksefjell H., Sandstad B., Trope C.: "Ovarian cancer Stage IIIC Consequences of treatment level on overall and progression-free survival". Eur. J. Gynaecol. Oneal., 2006, 27, 209.